Journal: Discover oncology

Article Title: Hepatoma cell-derived exosomal SNORD52 mediates M2 macrophage polarization by activating the JAK2/STAT6 pathway.

doi: 10.1007/s12672-024-01700-y

Figure Lengend Snippet: Fig. 3 SNORD52 mediates M2 macrophage polariza- tion and activates JAK2/ STAT6 pathway. A Following transfection of OE-SNORD52/ OE-NC in THP-1 and U937 for 48 h, the mRNA expression of SNORD52 was detected by qRT-PCR. ****P < 0.0001 vs. OE-NC. B Following trans- fection of OE-SNORD52/ OE-NC in THP-1 and U937 for 48 h, the protein levels of Arginase-1 and CD163 were determined through Western blotting. *P < 0.05, **P < 0.01, ***P < 0.001 vs. OE-NC. C The ratio of CD206-positive or CD163-positive cells following transfection of OE-SNORD52/ OE-NC was analyzed by flow cytometry. ***P < 0.001 vs. OE-NC. D Following transfec- tion of OE-SNORD52/OE-NC in THP-1 and U937 for 48 h, the levels of JAK2/STAT6 pathway-related proteins were determined through Western blotting. ***P < 0.001 vs. OE-NC. E The IL-4 and IL-13 treated THP-1/U937 mac- rophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the mRNA expression of SNORD52 was detected by qRT-PCR. *P < 0.05, **P < 0.01, ***P < 0.001 vs. ASO-NC. F The IL-4 and IL-13 treated THP-1/U937 mac- rophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the protein levels of Arginase-1 and CD163 were determined through Western blotting. ***P < 0.001 vs. ASO-NC. G The ratio of CD206-positive or CD163-positive cells following transfection of SNORD52- ASO-1/-2 or ASO-NC was analyzed by flow cytometry. ***P < 0.001 vs. ASO-NC. (H) The IL-4 and IL-13 treated THP-1/ U937 macrophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the levels of JAK2/STAT6 pathway-related proteins were determined through Western blotting. ***P < 0.001 vs. ASO-NC. ns: no significance

Article Snippet: Meanwhile, the primary antibodies Arginase-1, CD163, and STAT6 used in Western blotting were also purchased from Proteintech, while other primary antibodies including JAK2, p-JAK2, p-STAT6, exosome-positive markers (CD81 and TSG101), and the corresponding HRP-conjugated secondary antibodies were available from Abcam (Cambridge, UK).

Techniques: Transfection, Expressing, Quantitative RT-PCR, Western Blot, Flow Cytometry, Incubation

Journal: Discover oncology

Article Title: Hepatoma cell-derived exosomal SNORD52 mediates M2 macrophage polarization by activating the JAK2/STAT6 pathway.

doi: 10.1007/s12672-024-01700-y

Figure Lengend Snippet: Fig. 5 Huh7 cells-derived exosomal SNORD52 mediates M2 macrophage polarization through activating JAK2/STAT6 pathway. A Following the establishment of co-culture model, AG-490 (a specific JAK2 inhibitor) was added and the levels of JAK2/STAT6 pathway-related pro- teins in receptor THP-1 macrophages were measured by Western blotting. B Following the establishment of co-culture model, AG-490 (a specific JAK2 inhibitor) was added and the ratio of CD206-positive or CD163-positive THP-1 macrophages was analyzed by flow cytometry. **P < 0.01, ***P < 0.001. ns: no significance

Article Snippet: Meanwhile, the primary antibodies Arginase-1, CD163, and STAT6 used in Western blotting were also purchased from Proteintech, while other primary antibodies including JAK2, p-JAK2, p-STAT6, exosome-positive markers (CD81 and TSG101), and the corresponding HRP-conjugated secondary antibodies were available from Abcam (Cambridge, UK).

Techniques: Derivative Assay, Co-Culture Assay, Western Blot, Flow Cytometry

Journal: Oncology Research

Article Title: Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2 V617F mutation in myeloproliferative neoplasms

doi: 10.32604/or.2024.056256

Figure Lengend Snippet: Structural Analysis of JAK2 V617F Inhibitor Interactions: (a) Crystal structure of JAK2 V617F bound to EKT retrieved from the experimental structure 6G3C. The kinase domain of JAK2 is shown in blue, with the inhibitor EKT highlighted in green. (b) Protein-ligand interaction profile of compound 2 with JAK2 V617F . Key interacting residues (Lys630, Val629, Phe628, Glu627, Ile559, Leu551, Lys677, and Leu680) are highlighted, illustrating the critical binding interactions within the kinase domain.

Article Snippet: The assay was carried out by the manufacturer’s instructions using a luminescence-based JAK2 assay kit (Catalog #79520) from BPS Bioscience, San Diego, CA, USA.

Techniques: Binding Assay

Journal: Oncology Research

Article Title: Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2 V617F mutation in myeloproliferative neoplasms

doi: 10.32604/or.2024.056256

Figure Lengend Snippet: High-Throughput Virtual Screening Results: (a) Docking scores of the top molecules from the ChemBridge library screened against JAK2 V617F kinase. SBLJ23 is identified as the molecule with the highest binding affinity. (b) Comparative docking scores of SBLJ23, EKT, and staurosporine with JAK2 V617F and wild-type JAK2. SBLJ23 shows superior binding affinity to JAK2 V617F while maintaining selectivity over wild-type JAK2. (c) Binding mode of SBLJ23 within the kinase domain of JAK2 V617F . The compound fits well within the active site, forming stable interactions. (d) 2D representation of SBLJ23, illustrating the molecular structure and key functional groups.

Article Snippet: The assay was carried out by the manufacturer’s instructions using a luminescence-based JAK2 assay kit (Catalog #79520) from BPS Bioscience, San Diego, CA, USA.

Techniques: High Throughput Screening Assay, Binding Assay, Functional Assay

Journal: Oncology Research

Article Title: Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2 V617F mutation in myeloproliferative neoplasms

doi: 10.32604/or.2024.056256

Figure Lengend Snippet: PLIP of SBLJ23: (a) Detailed interaction profile of SBLJ23 with JAK2 V617F using Discovery Studio Visualizer. Key residues Cys675, Lys677, Leu680, and Leu579 are highlighted. (b) Types of interactions formed by SBLJ23 with JAK2 V617F , including pi-sulfur, pi-cation, and pi-alkyl bonds, contribute to the compound’s binding stability.

Article Snippet: The assay was carried out by the manufacturer’s instructions using a luminescence-based JAK2 assay kit (Catalog #79520) from BPS Bioscience, San Diego, CA, USA.

Techniques: Binding Assay

Journal: Oncology Research

Article Title: Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2 V617F mutation in myeloproliferative neoplasms

doi: 10.32604/or.2024.056256

Figure Lengend Snippet: Molecular Dynamics Simulation of SBLJ23 Binding: (a) Root Mean Square Deviation (RMSD) of SBLJ23 bound to JAK2 V617F over 100 ns. SBLJ23 shows stable binding after 15 ns, which stabilizes after 50 ns. (b) Snapshots of trajectory frames before and after the 100 ns MD simulation. The 0 ns frame shows the initial binding pose of SBLJ23, while the 100 ns frame shows additional interactions and a more stable binding conformation.

Article Snippet: The assay was carried out by the manufacturer’s instructions using a luminescence-based JAK2 assay kit (Catalog #79520) from BPS Bioscience, San Diego, CA, USA.

Techniques: Binding Assay

Journal: Oncology Research

Article Title: Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2 V617F mutation in myeloproliferative neoplasms

doi: 10.32604/or.2024.056256

Figure Lengend Snippet: Biological efficacy of SBLJ23: (a) The enzyme IC 50 values of SBLJ23 and staurosporine against the JAK2 enzyme, representing the mean ± standard deviation (SD) from three independent experiments. IC 50 values were determined using GraphPad Prism version 6.0 software. (b) The GI 50 values for cell proliferation in HEL, SET2, and UKE1 cells with the JAK2 V617F mutation and TF-1 cells with wild-type JAK2 when treated with SBLJ23. (c) Comparative inhibition of HEL cell proliferation when treated with different concentrations of SBLJ23 and Ruxolitinib. (d) The effect of SBLJ23 on the viability of Vero cells at various concentrations. Cell proliferation and viability assays were assessed using the MTT assay, with mean ± SD values analyzed using GraphPad Prism version 6.0 software. * p < 0.05, ** p < 0.01.

Article Snippet: The assay was carried out by the manufacturer’s instructions using a luminescence-based JAK2 assay kit (Catalog #79520) from BPS Bioscience, San Diego, CA, USA.

Techniques: Standard Deviation, Software, Mutagenesis, Inhibition, MTT Assay

Journal: Oncology Research

Article Title: Dibenzo [a, c] phenazin-11-yl(phenyl) methanone (SBLJ23), a novel selective inhibitor targeting JAK2 V617F mutation in myeloproliferative neoplasms

doi: 10.32604/or.2024.056256

Figure Lengend Snippet: The percentage of (a) phospho JAK2 or (b) phospho STAT3-positive population in HEL cells treated with SBLJ23 was assessed using flow cytometry. Numerical values represent the mean ± standard deviation (SD) from multiple experiments. Pretreatment with different doses of SBLJ23 led to a reduction in both phospho JAK2 and phospho STAT3 populations in HEL cells.

Article Snippet: The assay was carried out by the manufacturer’s instructions using a luminescence-based JAK2 assay kit (Catalog #79520) from BPS Bioscience, San Diego, CA, USA.

Techniques: Flow Cytometry, Standard Deviation

Journal: Studies in Mycology

Article Title: Aspergillus , Penicillium and Talaromyces isolated from house dust samples collected around the world

doi: 10.1016/j.simyco.2014.07.002

Figure Lengend Snippet: Strains used for phylogenetic analyses of new Aspergillus , Penicillium and Talaromyces species described from house dust.

Article Snippet: A. brevijanus , CBS 111.46 = NRRL 1935 = ATCC 16828 = CBS 119.45 = IMI 016066ii = IMI 16066 = NCTC 6971 = QM 7417 = WB 1935 , EF669582 , EU014078 , EF669540.

Techniques: